SOC Telemed announces a departure from the CFO, Chris Knibb
The largest national provider of acute care telemedicine, announced today that Chris Knibb, Chief Financial Officer (CFO) has resigned to pursue other opportunities by September 23, 2021. The Company will begin its search for a new CFO immediately. David Fletcher was appointed interim CFO, while SOC searches to find a successor. Mr. Knibb will be available to support the transition through December 31, 2021.
"I appreciate Chris' leadership and impact on the SOC team," said Dr. Chris Gallagher, Chief Executive Officer of SCS Telemed. "We wish Chris luck and trust our finance team's leadership as we work to find a successor."
David Fletcher will serve as interim Chief Financial Officer of SOC Telemed. Mr. Fletcher is a financial consultant currently working as an interim chief financial offer and senior finance executive of healthcare, technology and services companies sponsored by leading private equity companies, including Goldman Sachs, H.I.G. Capital
Before Tatum began, he was a CEO and Chief Financial Officer of three publicly traded companies: American Realty Investors, Inc., Transcontinental Realty Investments Inc, and Income Opportunity Investment Investment. Mr. Fletcher, previously president and chief financial officer of a wholly-owned subsidiary of Tarragon Corporation, which had its common stock listed and traded on the NASDAQ, was employed as supper with Deloit
Mr. Fletcher holds a bachelor of Business Administration and focuses his research in finance at the University of Texas at Austin. He was accepted into the Sord Scholar's class as an academic. Mr. Fletcher is a graduate of the University of Iowa, as well as he holds scalding degrees in Business Administration.
Financial guidance for 2021. SOC is taking the opportunity to reaffirm the financial guidance that the company gave during its second quarter earnings call on Thursday, August 12, 2021.
- GAAP Revenue will be expected to be in the range between 90 and 90 million dollars, and approximately 30 percent will likely be attributed to Access Physicians.
- The guidance focuses on the use of the Delta variant of COVID-19, particularly on increased pressure on hospital emergency departments, and a change in go-to-market strategy that would support access physicians' access, as well as the
- The gross margin adjusted is expected to be 37.0% and 40.00%.
- The adjusted EBITDA is expected to be between $22 and $225 million dollars.
These statements are forward-looking and actual results may differ materially. Please read the Forward-Looking Statements safe harbor below for more information about the factors that could cause our actual results to differ materially from these forward-looking statements.
SOC Telemed has not reconciled its expectations for adjusted gross margin and adjusted EBITDA to the most comparable GAAP measures because certain items are out of control or can be reasonably calculated or predicted at this time without unreasonable efforts. In any case, the reconciliation for forward-looking Adjusted Gross Margin and Adjustable EBITDA is not available without unreasonable effort.
About SOC Telemed About Telemmed TeleMed Telecam.
SOC Telemed (NASDAQ: TLMD, "SOC") is the leading national provider of acute telemedicine technology and solutions to hospitals, hospitals and healthcare systems, post-academic providers, physician networks and value By using a proven and scalable infrastructure as an enterprise-wide solution, SOC's technology platform Telemed IQ rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a dedicated and supportive partner presence, capable of providing patient care through teleneurology, tietology, devt., and fpc, all service lines, as well as SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes and organizational health. The company was the first provider of acute clinical telemedicine services to earn the Gold Seal of Approval of the Joint Commission in the years to the point of founding. Since then, the company has maintained that accreditation every year. For more information, visit www.soctelemed.com.
Statements with a view to the future are expected to arrive with anticipation.
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of United States Private Securities Litigation Reform Act of 1995. Some cases, you can identify these forward-looking statements by using terms such as "expect," "will," or similar expressions, and variations or negatives of these words, but this doesn't mean a statement is Any statements other than historical statements are statements that can be considered forward-looking statements, including, but not limited to, statements under the "2021 Financial Guidance" and any other statements of expectation or belief. The real and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from the results expressed or implied in this press release. These risks are based on the factors of the In the Risk Factors section of SOC Telemed's most recent quarterly report on Form 10-Q, and in the subsequent filings with the U.S. Securities and Exchange Commission. SOC Telemed assumes no obligation to update these forward-looking statements as a result of future events or developments, and does not intend to change them, except as required by law. Readers should not place unreasonable reliance on forward-looking statements that speak only from the date of this date.
Media Relations: Lauren Shankman Trevelino/Keller Lauren Yong-Yang Minh-Siyang. [email protected]
Investor Relations: a contract with crows. Steve Rubis Vice President, Investor Relations SOC Telemed P: (214) 681-7991, 71%. [email protected]
SOURCE SOC Telemed SURCE CITY Telecast S.
http://www.soctelemed.com/www/odo.html is a site for those who don't have any interest in the technology.